Maravai LifeSciences(MRVI) - 2024 Q1 - Earnings Call Presentation

Financial Performance - Q1 2024 revenue reached $64 million[23] - Nucleic Acid Production (NAP) revenue was $46 million, representing 72% of total revenue[11, 57] - Biologics Safety Testing (BST) revenue was $18 million, accounting for 28% of total revenue[29, 77] - Adjusted EBITDA for Q1 2024 was $8 million[6] - The company reported a GAAP Net Loss of $23 million[37] - Adjusted loss per share was $(0.02)[11] Financial Position - The company holds a strong cash position of $562 million[13] - Net cash stands at $30 million[13] - Long-term debt is $532 million[30] - Adjusted Free Cash Flow was $4 million in Q1 2024[30, 75] Innovation and Expansion - The company is expanding resources to build credibility and long-term opportunity, including mRNA catalog refresh with 21 new products[15] - Cygnus Technologies kits are now used in all 21 FDA-approved CAR-T Cell and Gene Therapies for lot release[41]